Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-06-24

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003667

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma of the Skin

First Posted Date: 2004-06-24

Last Posted Date: 2012-10-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 80

Registration Number: NCT00003549

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 81 locations

Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Cyclophosphamide
Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Autologous Bone Marrow Transplantation
Radiation: Total Body Irradiation (TBI)

First Posted Date: 2004-06-23

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00002844

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Phase 2

Completed

Conditions: Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: bleomycin sulfate
Biological: recombinant interferon alfa
Drug: cyclophosphamide
Drug: cytarabine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2004-06-22

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 20

Registration Number: NCT00002657

Locations: 🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 83 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: Filgrastim (G-CSF)
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-06-16

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00002838

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-06-16

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Registration Number: NCT00002785

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

and more 30 locations

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Phase 3

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Radiation: Craniospinal Irradiation
Drug: Cyclophosphamide
Radiation: Involved-Field Radiation Therapy
Drug: Lomustine
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Vincristine Sulfate

First Posted Date: 2004-06-16

Last Posted Date: 2024-11-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 549

Registration Number: NCT00085735

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 194 locations

Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2004-06-16

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 34

Registration Number: NCT00003829

Locations: 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States
🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States

and more 14 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: mesna
Drug: vincristine sulfate
Procedure: conventional surgery
Procedure: peripheral blood stem cell transplantation
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-06-16

Last Posted Date: 2014-07-24

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 30

Registration Number: NCT00002740

Locations: 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States

and more 4 locations

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: aldesleukin
Biological: sargramostim
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2004-06-11

Last Posted Date: 2013-04-10

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 20

Registration Number: NCT00085423

Locations: 🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy